Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PETX

Aratana Therapeutics (PETX) Stock Price, News & Analysis

Aratana Therapeutics logo

About Aratana Therapeutics Stock (NASDAQ:PETX)

Key Stats

Today's Range
$4.92
$4.92
50-Day Range
$4.92
$4.92
52-Week Range
$3.30
$7.16
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$241.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PETX Stock News Headlines

PETX_old Historical Data
Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
5 Stocks Under $10 to Trade for Big Breakouts
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
See More Headlines

PETX Stock Analysis - Frequently Asked Questions

Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative trailing twelve-month return on equity of 12.99%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
11/01/2018
Today
10/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PETX
CIK
1509190
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.72 million
Net Margins
-33.47%
Pretax Margin
N/A
Return on Equity
-12.99%
Return on Assets
-10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.66
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$35.41 million
Price / Sales
6.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
49,000,000
Free Float
N/A
Market Cap
$241.08 million
Optionable
Optionable
Beta
1.40
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PETX) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners